Related Experiment Video

Updated: Sep 24, 2025

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.0K

The future of targeted kinase inhibitors in melanoma

Signe Caksa1, Usman Baqai1, Andrew E Aplin2

  • 1Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.

Pharmacology & Therapeutics
|May 5, 2022
PubMed

Insights

Targeted kinase inhibitors show promise for melanoma treatment, offering improved survival for BRAF-mutant cases. Future research focuses on overcoming resistance and expanding applications in rare subtypes through combination therapies and personalized medicine.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Melanoma incidence is increasing globally.
  • Targeted MAPK pathway kinase inhibitors improve survival in BRAF-mutant metastatic cutaneous melanoma.
  • Drug resistance and limited efficacy in rare melanoma subtypes present challenges.

Purpose of the Study:

  • To explore the future applications of targeted kinase inhibitors in melanoma treatment.
  • To address limitations of current therapies, including drug resistance and efficacy in rare subtypes.
  • To highlight the potential of novel combinations and personalized medicine approaches.

Main Methods:

  • Review of current therapeutic strategies for melanoma.
  • Analysis of pre-clinical studies identifying tumor dependencies and drug targets.
  • Evaluation of emerging applications like adjuvant/neoadjuvant therapy and combination treatments.

Main Results:

  • Targeted kinase inhibitors are effective in BRAF-mutant melanoma but face resistance.
  • Rare melanoma subtypes show minimal response to MAPK pathway inhibitors.
  • Pre-clinical research is identifying new targets for combination therapies.

Conclusions:

  • Targeted kinase inhibitors have a future in melanoma, particularly in combination therapies and personalized medicine.
  • Novel applications include adjuvant/neoadjuvant settings and combinations with immunotherapies.
  • Identifying tumor dependencies will drive rational, personalized treatment strategies for melanoma.
Keywords:
CancerCombination therapyImmune checkpoint inhibitorsKinase inhibitorsMelanomaTargeted therapy

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.9K